Aurobindo Pharma Gains 5%; BSE HEALTHCARE Index Up 1.0%
Wed, 23 Apr 15:39
Image source: ipopba/www.istockphoto.comAurobindo Pharma share price has zoomed 5% and is presently trading at Rs 1,252.0.
Meanwhile, the BSE HEALTHCARE index is at 42,693.0 (up 1.0%).
Among the top gainers in the BSE HEALTHCARE index today are ALKEM LABORATORIES (up 4.5%) and ERIS LIFESCIENCES (up 4.1%).
J.B.Chemicals (down 4.1%) and SUVEN PHARMACEUTICALS (down 2.6%) are among the top losers today.
Over the last one year, Aurobindo Pharma has moved up from Rs 1,076.1 to Rs 1,252.0, registering a gain of Rs 175.9 (up 16.3%).
On the other hand, the BSE HEALTHCARE index has moved up from 34,783.5 to 42,693.0, registering a gain of 22.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 88.4%), KIMS (up 76.3%) and ASTRAZENECA PHARMA (up 73.0%).
Time Sensitive: Access Our 4 Foundational Stock Recommendation Services at 75% OFF
What About the Benchmark Indices?
The BSE Sensex is at 80,116.5 (up 0.7%).
The top gainers among the BSE Sensex today are HCl Tech. (up 7.7%) and Tech Mahindra (up 4.9%). The most traded stocks in the BSE Sensex are Tata Motors and ZOMATO.
In the meantime, NSE Nifty is at 24,329.8 (up 0.7%). HCl Tech. and Tech Mahindra are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 73,648.6 to 80,116.5, registering a gain of 6,467.9 points (up 8.8%).
Aurobindo Pharma Financial Update...
Aurobindo Pharma net profit fell 10.5% YoY to Rs 8,440 million for the quarter ended December 2024, compared to a profit of Rs 9,426 million a year ago. Net sales rose 8.5% to Rs 79,785 million during the period as against Rs 73,518 million in October-December 2023.
For the year ended March 2024, Aurobindo Pharma reported 64.4% increase in net profit to Rs 31,690 million compared to net profit of Rs 19,277 million during FY23. Revenue of the company grew 16.7% to Rs 290,019 million during FY24.
The current Price to earnings ratio of Aurobindo Pharma, based on rolling 12 month earnings, stands at 20.8.
Indian Share Market Update: Top Gainers and Losers
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
- Hidden Treasure
- Forever Stocks
- Big Wave Profits
- Equitymaster Venture
- Microcap Millionaires
- Momentum Profits
- Double Income
- Midcap Value Alert
- Exponential Profits
- Annual Breakout Alert
- Lazy Millionaire
- Phase One Alert
- InsiderPro Stocks
- StockSelect
- Private Briefing
- Active Wealth Multiplier 2030
- FundSelect
- Fund Advantage
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
- Best Defence Stocks in India
- Upcoming Dividend Stocks
- Best Semiconductor Stocks in India
- Data Center Stocks in India
- Best Railway Stocks in India
- Best Solar Stocks in India
- Fastest Growing Stocks in India
- List of BSE Sensex 30 Stocks
- Adani Group Shares
- Stocks Recently Bought by FIIs in India
- Top Value Stocks in India
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.
Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.
The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.
Equitymaster requests your view! Post a comment on "Aurobindo Pharma Gains 5%; BSE HEALTHCARE Index Up 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!